Bad News for Transcranial Magnetic Stimulation
The Carlat Psychiatry Report, Volume 5, Number 3, March 2007
https://www.thecarlatreport.com/newsletter-issue/tcprv5n3/
Issue Links: Learning Objectives | Editorial Information
Topics: Antidepressants
William Carpenter, MD
An FDA advisory panel has recommended that TMS not be approved for the treatment of major depression. Neuronetics, the maker of the NeuroStar device (www.neuronetics.com), submitted data from three studies, but only one was a placebo-controlled double-blind trial (Study 101).
You can't view details of this content, please login or buy subscription here
William Carpenter, MD
Editor-in-Chief, Schizophrenia Bulletin; Professor, Psychiatry and Pharmacology, and Director, Maryland Psychiatric Research Center University of Maryland School of Medicine, Baltimore
Dr. Carpenter has disclosed that he has served as a consultant to Alza, AstraZeneca, Janssen Pharmaceutica, Merck, Pfizer, and Solvay/Wyeth, and that he has received less than $5,000 for each consultancy. Dr. Carlat has reviewed and edited the content to ensure a balanced and unbiased presentation.